Tranexamic Acid 500 mg Tablets

PL 06464/2913

LAY SUMMARY

The Medicines and Healthcare products Regulatory Agency (MHRA) granted Waymade Plc (trading as Sovereign Medical) a Marketing Authorisation (licence) for the medicinal product, Tranexamic Acid 500 mg Tablets on 19 April 2013. This is a prescription-only medicine (POM).

The active ingredient, tranexamic acid, belongs to a group of medicines called anti-fibrinolytic drugs. These are used to stop or reduce bleeding. When you bleed (through injury) your body forms clots as part of the healing process. In some people these blood clots do not stay in place long enough, causing too much bleeding to occur. Tranexamic acid helps these clots to stay in place.

Tranexamic Acid 500 mg Tablets are used to prevent or reduce bleeding for a short period of time in many different conditions. Tranexamic Acid 500 mg Tablets may be prescribed in the following conditions:

- following prostate surgery (prostatectomy) or bladder surgery
- heavy periods (menorrhagia)
- nose bleeds (epistaxis)
- cervical surgery
- bleeding in the eye (traumatic hyphaema)
- tooth removal in haemophiliacs (people with inherited blood clotting disorder)
- hereditary angioneurotic oedema (a doctor would have told you if you have this condition).

This application is a duplicate of a previously granted application for Tranexamic Acid 500 mg Tablets (PL 06464/1373), which was authorised to the Marketing Authorisation Holder Waymade Plc (trading as Sovereign Medical) on 18 August 2003.

No new or unexpected safety concerns arose from this simple application and it was, therefore, judged that the benefits of taking Tranexamic Acid 500 mg Tablets outweigh the risks, hence a Marketing Authorisation has been granted.
Tranexamic Acid 500 mg Tablets

PL 06464/2913

SCIENTIFIC DISCUSSION

TABLE OF CONTENTS

Introduction Page 4
Pharmaceutical assessment Page 5
Non-clinical assessment Page 8
Clinical assessment Page 9
Overall conclusion and benefit/risk assessment Page 10
INTRODUCTION

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a Marketing Authorisation for the medicinal product Tranexamic Acid 500 mg Tablets (PL 06464/2913) on 19 April 2013. This is a prescription-only medicine (POM) and indicated for:

1. Short-term use for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Local fibrinolysis as occurs in the following conditions:
   a) Prostatectomy and bladder surgery
   b) Menorrhagia
   c) Epistaxis
   d) Conisation of the cervix
   e) Traumatic hyphaema
2. Hereditary angioneurotic oedema
3. Management of dental extraction in haemophiliacs.

The active ingredient, tranexamic acid, belongs to a group of medicines called anti-fibrinolytic drugs. Tranexamic acid is a potent competitive inhibitor of the activation of plasminogen to plasmin. At much higher concentrations it is a non-competitive inhibitor of plasmin. The inhibitory effect of tranexamic acid in plasminogen activation by urokinase has been reported to be 6-100 times and by streptokinase 6-40 times greater than that of aminocaproic acid. The antifibrinolytic activity of tranexamic acid is approximately ten times greater than that of aminocaproic acid.

This application was submitted as a simple abridged application, according to Article 10(c) of Directive 2001/83/EC, as amended, cross-referring to Tranexamic Acid 500 mg Tablets (PL 06464/1373) authorised on 18 August 2003 to the Marketing Authorisation Holder Waymade Plc (trading as Sovereign Medical).

No new data were submitted nor were they necessary for this simple application, as the data are identical to these of the previously granted cross-reference product.
1. INTRODUCTION
This is a simple, informed consent application for Tranexamic Acid 500 mg Tablets submitted under Article 10c of Directive 2001/83/EC, as amended. The proposed Marketing Authorisation Holder is Waymade Plc trading, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom.

The application cross-references to Tranexamic Acid 500 mg Tablets (PL 06464/1373), for which a Marketing Authorisation was granted to Waymade Plc (trading as Sovereign Medical) on 18 August 2003.

The current application is considered valid.

2. MARKETING AUTHORISATION APPLICATION FORM
2.1 Name(s)
The proposed name of the product is Tranexamic Acid 500 mg Tablets. The product has been named in line with current requirements.

2.2 Strength, pharmaceutical form, route of administration, container and pack sizes
The product is for oral administration. Each tablet contains 500 mg tranexamic acid.

Tranexamic Acid 500 mg Tablets are packaged in aluminium/polyvinyl chloride (PVC) blister packs in packs of 12 or 60 tablets.

The proposed shelf-life (36 months) and storage conditions (Do not store above 25°C; Store in the original package) are consistent with the details registered for the cross-reference product.

2.3 Legal status
On approval, the product will be available as a prescription-only medicine (POM).

2.4 Marketing Authorisation Holder/Contact Persons/Company
The Marketing Authorisation Holder is Waymade Plc (trading as Sovereign Medical), Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom.

The Qualified Person (QP) responsible for pharmacovigilance is stated and their CV is included.

2.5 Manufacturers
The proposed manufacturing sites are consistent with those registered for the cross-reference product and evidence of Good Manufacturing Practice (GMP) compliance has been provided.

2.6 Qualitative and quantitative composition
The proposed composition is consistent with the details registered for the cross-reference product.

2.7 Manufacturing process
The proposed manufacturing process is consistent with the details registered for the cross-reference product and the maximum batch size is stated.

2.8 Finished product/shelf-life specification
The proposed finished product specification is in line with the details registered for the cross-reference product.

2.9 Drug substance specification
The proposed drug substance specification is consistent with the details registered for the cross-reference product.

2.10 TSE Compliance
With the exception of magnesium stearate, no materials of animal or human origin are included in the product. This is consistent with the cross reference product.

The applicant has provided TSE Certificates of Suitability to show that magnesium stearate is provided from appropriate sources.

None of the excipients are sourced from genetically modified organisms.

2.11 Bioequivalence
No bioequivalence data are required to support this simple abridged informed consent application, as the proposed product is manufactured to the same formula utilising the same process as the cross-reference product Tranexamic Acid 500 mg Tablets (PL 06464/1373).

3. EXPERT REPORTS
The applicant cross-refers to the data for Tranexamic Acid 500 mg Tablets (PL 06464/1373), to which they claim identicality. This is acceptable.

4. PRODUCT NAME & APPEARANCE
See 2.1 for details of the proposed product name. The appearance of the product is identical to the respective cross-reference product.

5. SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)
The proposed SmPC is consistent with the details registered for the cross-reference product.

6. PATIENT INFORMATION LEAFLET (PIL) AND LABELLING
PIL
The patient information leaflet has been prepared in line with the details registered for the cross-reference product.
This PIL was submitted to the MHRA along with results of consultations with target patient groups (‘user testing’), in accordance with Article 59 of Council Directive 2001/83/EC, as amended. The results indicate that the leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.
As the content of the leaflets for the reference product and this product are considered the same, no further user testing of the leaflet for this product is necessary.

Carton and blister
The proposed artwork is comparable to the artwork registered for the cross-reference product and complies with statutory requirements. In line with current legislation, the applicant has also included the name of the product in Braille on the outer packaging.
7. CONCLUSIONS
The data submitted with this application is acceptable. The grant of a Marketing Authorisation is recommended.
NON-CLINICAL ASSESSMENT

No new non-clinical data have been submitted with this application and none are required for an application of this type.

The Marketing Authorisation Holder has provided adequate justification for not submitting an Environment Risk Assessment (ERA). As the application is for an identical version of an already authorised reference product, it is not expected that the environmental exposure to tranexamic acid will increase following the marketing approval of the product.

The grant of a Marketing Authorisation is recommended.
CLINICAL ASSESSMENT

No new clinical data have been submitted with this application and none are required for an application of this type.

The Marketing Authorisation Holder has provided details of a suitable pharmacovigilance system that fulfils the requirements and provides adequate evidence that the Marketing Authorisation Holder has the services of a Qualified Person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

The Marketing Authorisation Holder has provided an adequate justification for not submitting a Risk Management Plan (RMP). As the application is for an identical version of an authorised reference product, for which safety concerns requiring additional risk minimisation have not been identified, a risk minimisation system is not considered necessary. The reference product has been in use for many years and the safety profile of the active ingredient is well-established.

The grant of a Marketing Authorisation is recommended.
OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

QUALITY
The data for this application is consistent with data previously assessed for the cross-reference product and as such the data have been judged to be satisfactory.

NON-CLINICAL
No new non-clinical data were submitted and none are required for an application of this type.

EFFICACY
This application is identical to the previously granted application for Tranexamic Acid 500 mg Tablets (PL 06464/1373; Waymade Plc).

SAFETY
No new or unexpected safety concerns arise from this application.

PRODUCT LITERATURE
The SmPC, leaflet and labelling are satisfactory and consistent with those for the cross-reference product.

BENEFIT/RISK ASSESSMENT
The quality of the product is acceptable and no new non-clinical or clinical safety concerns have been identified. The applicant’s product is identical to the cross-reference product. Extensive clinical experience with tranexamic acid is considered to have demonstrated the therapeutic value of the compound. The benefit/risk is, therefore, considered to be positive.
Tranexamic Acid 500 mg Tablets

PL 06464/2913

STEPS TAKEN FOR ASSESSMENT

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The MHRA received the Marketing Authorisation application on 05 March 2012.</td>
</tr>
<tr>
<td>2</td>
<td>Following standard checks and communication with the applicant the MHRA</td>
</tr>
<tr>
<td></td>
<td>considered the application is valid on 04 May 2012.</td>
</tr>
<tr>
<td>3</td>
<td>Following assessment of the application the MHRA requested further information on 09 August 2012.</td>
</tr>
<tr>
<td>4</td>
<td>The applicant responded to the MHRA’s request, providing further information on 18 December 2012.</td>
</tr>
<tr>
<td>5</td>
<td>The application was determined on 19 April 2013.</td>
</tr>
</tbody>
</table>
Tranexamic Acid 500 mg Tablets

PL 06464/2913

STEPS TAKEN AFTER ASSESSMENT

<table>
<thead>
<tr>
<th>Date submitted</th>
<th>Application type</th>
<th>Scope</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tranexamic Acid 500 mg Tablets

PL 06464/2913

SUMMARY OF PRODUCT CHARACTERISTICS

In accordance with Directive 2010/84/EU, the Summaries of Product Characteristics (SmPCs) for products granted Marketing Authorisations at a national level are available on the MHRA website.
PRODUCT INFORMATION LEAFLET

In accordance with Directive 2010/84/EU, the Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website.